XERS Stock — Xeris Biopharma Holdings Inc.: Cash, EV, Pipeline

What they do

We offer Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing’s syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis ("PPP"). We are advancing our Phase 3-ready pipeline product, XP-8121, once-weekly subcutaneous ("SC") levothyroxine, which leverages our proprietary technology XeriSol.

Source: 10-K FY2025 via SEC EDGAR

Share price

$16.41

Market cap

$2,996.3M

Cash

$131.1M

Enterprise value

$3,118.7M

Balance sheet

Cash	$131.1M
Debt	$253.5M
Net cash	-$122.4M
Enterprise value	$3,118.7M
Basic shares	182.7M shares
Fully diluted shares	217.6M shares
Fully diluted market cap	$3,570.7M
Cash per share	$0.72
Quarterly burn	+$8.3M generated

Cash figures as of 2026-09-30. Database snapshot: 2026-11-11.

Share structure

Common

182.3M

Pre-funded warrants

0.0M

Options

7.1M

RSUs

0.0M

Warrants

0.0M

Converts

28.2M

Conv preferred

0.0M

ESPP reserve

—

FDSO

217.6M

Cap table as of 2026-10-31.

Price history

Loading XERS daily closes…

Loading price history…

Upcoming catalysts

No upcoming catalysts on file for this company.

Full readout calendar →

Pipeline assets

Recorlev

Approved · Active Modality: small molecule (cortisol synthesis inhibitor, oral)

Aliases levoketoconazole

Target 11-beta-hydroxylase (cortisol synthesis inhibition)

Indications

Endogenous hypercortisolemia in adult patients with Cushing's syndrome (surgery not an option or not curative) (Approved)

Status note Approved for endogenous hypercortisolemia in Cushing's syndrome. Subject to generic ANDA litigation.

Gvoke

Approved · Active Modality: peptide injection (ready-to-use liquid-stable glucagon; XeriSol formulation)

Aliases glucagon

Target glucagon receptor

Indications

Severe hypoglycemia (diabetes, pediatric and adult patients age 2+) (Approved)

Status note Approved ready-to-use glucagon (PFS, HypoPen, Kit) for severe hypoglycemia.

Keveyis

Approved · Active Modality: small molecule (oral)

Aliases dichlorphenamide

Target carbonic anhydrase inhibitor

Indications

Primary Periodic Paralysis (PPP): hyperkalemic, hypokalemic, and related variants (Approved)

Status note First US therapy approved for hyperkalemic, hypokalemic, and related PPP variants.

XP-8121

Phase 2 · Active Modality: peptide injection (once-weekly subcutaneous levothyroxine; XeriSol formulation)

Indications

Hypothyroidism (Phase 2)

Status note Phase 3-ready; working with FDA and planning to initiate a Phase 3 trial of once-weekly SC levothyroxine. No Phase 3 start date disclosed.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Perceptive Advisors	467,013	+467,013	0.06%	2026-08-14
Stonepine Capital	0	-40,030	0.00%	2026-08-17

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

XERS — Xeris Biopharma Holdings Inc. ☆

What they do

Balance sheet

Share structure

Price history

Upcoming catalysts

Pipeline assets

Specialist fund holders

Latest news

XERS — Xeris Biopharma Holdings Inc.